Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
4 United States sites
18 to 50 Years
Phase 1/Phase 2
Vaso-occlusive crisis in Sickle cell disease might alter myocardial function through micro vascular obstruction.
1 France site
> 18 Years
Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.
1 Brazil site
18 to 60 Years
N/A
Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually.
1 Uganda site
3 to 9 Years
Sickle Cell Anaemia, SCA
Phase 3
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).
1 United States site
2 to 30 Years
Early Phase 1
This study will evaluate two genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) products - OTQ923 and HIX763 - each reducing the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
3 United States sites
2 to 40 Years
HbSS, HbSC
Phase 1/Phase 2
This pilot research is aimed to assess the needs of patients and health workers involved in Sickle Cell Disease (SCD) management in Nigeria.
4 Nigeria sites
> 18 Years
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
1 United States site
2 to 60 Years
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.
2 United States sites
1 Canada site
> 18 Years
Phase 1/Phase 2
This is a single arm pilot study of peripheral stem cell transplantation (PSCT) with ex vivo t-cell receptor alpha beta+(TCRαβ+) T cell and cluster of differentiation 19+ beta (CD19+ B) cell depletion of unrelated donor (URD) grafts using the CliniMACS device in patients with sickle cell disease (SCD) and beta thalassemia major (BTM).
1 United States site
2 to 25 Years
Hemoglobin SS, Hemoglobin SC
N/A
